SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA's upcoming earnings are driving intense speculation, with the community divided on whether the results will justify the current valuation amid broader AI concerns. Options market activity suggests caution, with some bracing for volatility and a potential downside if the chipmaker's report doesn't exceed expectations significantly. Bullish sentiment remains, tied to the company's long-term potential and key partnerships.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to renewed speculation around a potential buyout following Pfizer's acquisition of Metsera. The community is actively discussing the company's Phase 3 trial enrollment completion and potential partnerships, with some anticipating a significant announcement soon. GPCR ACCESS data is also being monitored for potential read-across implications.

Founded in 2015, Gnosis has evolved into a full-stack ecosystem bridging decentralised technology with everyday finance. Gnosis’ mission is to empower every person with greater financial agency and access, while supporting the creation of an open and collectively-owned financial system that benefits all. From its origins in decentralised prediction markets, Gnosis has grown into a full-spectrum provider spanning asset management, decentralised trading, and payments. Its industry-leading innovations include Safe, securing over $58 billion in assets; CoW Protocol, which has protected more than $130 billion in trades; and Gnosis Pay, enabling over $100m in payments to date, via crypto-native cards, for a growing ecosystem of wallets. Gnosis delivers a seamless, collectively-owned financial experience that puts accessibility and ownership at its core.

Gnosis

Gnosis ($GNO) is trending as community members anticipate a price surge, with some projecting it could reach $1000 soon, leading to increased discussion around accumulating the token. The bullish sentiment is fueled by its limited supply and perceived potential within the DeFi space, with comparisons being drawn to Berkshire Hathaway's role in traditional finance.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending amid speculation around deep-sea mining permits and potential government partnerships, fueled by the CEO's recent visit to Washington D.C. The community is discussing potential upside from government stakes and comparing TMC to other critical mineral companies. Bullish investors view any dip as a buying opportunity, anticipating long-term gains from deep-sea nodule extraction.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

NET is trending as retail investors express strong bullish sentiment despite recent volatility linked to a network outage. Community discussions revolve around the company's response to the outage and its valuation in relation to peers in the cloud security sector. Options activity and analyst ratings updates also appear to be influencing investor interest.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is trending amid ongoing speculation about a potential acquisition by Nestle, particularly given Nestle's existing investment and board presence; the community is weighing the possibility of a buyout versus a partnership, and how recent cost-cutting measures might impact a deal, while closely monitoring SEC filings and insider activity for clues.

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience Corp

TWST is trending amid discussions around earnings, revenue growth, and margin improvement, alongside a recent analyst upgrade. The community is weighing the company's path to profitability and potential for growth in synthetic DNA and NGS. Option activity and potential short squeeze are also contributing to the stock's increased attention.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as investors discuss the potential impact of sovereign AI contracts and a possible strategic partnership, with speculation around a major announcement that could be a "game changer". Community members are focused on the company's potential expansion in the Middle East and Europe, as well as the possibility of securing significant government and military contracts. Discussions also highlight potential partnerships, with some suggesting Palantir as a likely candidate, driving both excitement and volatility around the stock.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining attention, with the community emphasizing its strong cultural roots and positioning it as the 'Bitcoin' of cannabis on the Solana blockchain. Discussions highlight the project's focus on creativity, positivity, and innovation within the cannabis culture. Community members are actively promoting Weedcoin's vision and encouraging participation through various social media channels and online spaces.

Cracker Barrel Old Country Store, Inc. engages in the operation and development of restaurant and retail outlets. The format of its stores consists of a trademarked rustic old country-store design that offers restaurant menu featuring home-style country food. The company was founded by Dan W. Evins on September 19, 1969 and is headquartered in Lebanon, TN.

Cracker Barrel Old Country Store Inc

CBRL is trending amid discussions surrounding its financial performance, upcoming shareholder meeting, and ongoing debates about the current CEO's leadership. The community is focused on potential leadership changes and whether the company can revitalize its brand, with some speculating about a possible take-private scenario. Investors are closely watching key dates and events that may impact the stock's trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Recommendation of "Hold" from Brokerages

Shares of Novavax, Inc. (NASDAQ:NVAX - Get Free Report) have earned a consensus recommendation of "Hold" from the nine research firms that are covering the stock, Marketbeat Ratings reports. Four...

Quinn Opportunity Partners LLC Has $1.20 Million Holdings in Novavax, Inc. $NVAX

Quinn Opportunity Partners LLC lifted its position in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 63.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The...

Campbell & CO Investment Adviser LLC Takes $1.19 Million Position in Novavax, Inc. $NVAX

Campbell & CO Investment Adviser LLC acquired a new position in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) in the second quarter, according to its most recent filing with the Securities...

B. Riley Issues Pessimistic Outlook for Novavax Earnings

Novavax, Inc. (NASDAQ:NVAX - Free Report) - Equities research analysts at B. Riley decreased their Q4 2025 EPS estimates for shares of Novavax in a research note issued on Monday, November 10th. B...

<ul class="summary-bullets"><li>Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial results has become “striking.”</li><li>The fund urged the board to form a committee to evaluate alternatives and hire an investment bank, saying the company’s execution and market share have fallen far short of expectations.</li><li>Retail traders on Stocktwits voiced frustration with leadership, with some calling for shareholder coordination to support Shah’s campaign.</li></ul>Novavax’s retail traders turned cautious on Stocktwits as activist investor Shah Capital escalated its campaign for sweeping changes at the vaccine maker, warning it may launch a proxy fight if the board does not act within four months.<h2 class="st-heading-2">Shah Capital Presses For A Sale</h2>Shah Capital, Novavax’s second-largest shareholder, sent its second letter to the board in less than a month, saying it has become “increasingly disenchanted” with the company’s weak sales of its protein-based Covid-19 vaccine. In an interview, fund founder Himanshu Shah said that if he does not see progress within the next four months, “then I think that is definitely a potential for a proxy fight,” according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/transactional/shah-capital-pushes-novavax-sale-warns-proxy-fight-2025-11-12/">report</a>.The fund said it still believes in Novavax’s science and has raised its stake to about 8.3%, up from 7.2% in October. However, it said it remains “at a complete loss” over the disappointing commercial performance of Novavax’s vaccine, which sold roughly 120,000 doses through Oct. 31 during the 2025–2026 season, compared with 14.5 million doses sold by two competitors over the same period.Shah Capital said the “disconnect between potential and execution is striking,” and questioned whether Novavax and its commercial partner were showing “a profound lack of competence or intentionally underperforming.” It urged the board to immediately form a committee to evaluate strategic alternatives, including a sale, and to hire an investment bank to support the process. The fund has previously named Sanofi, Merck, GSK and AstraZeneca as potential buyers, though it said it has not contacted them.<h2 class="st-heading-2">Company Performance And Delays Add Pressure</h2>Earlier this month, Novavax pushed back its profitability target to 2028, a year later than previously expected. Shah said the company must reduce its high cost base, deliver operational profitability next year, and conduct more comprehensive trials. He valued the company at $5 billion to $10 billion, compared with a current market capitalization of about $1.21 billion, according to LSEG data.<h2 class="st-heading-2">Stocktwits Traders Voice Frustration</h2>On Stocktwits, retail sentiment for Novavax was ‘neutral’ amid ‘normal’ message volume.<figure class="image"><img style="aspect-ratio:974/141;" src="https://news.stocktwits-cdn.com/nvax_ss_jpg_71e1c4d6a0.webp" alt="nvax ss.jpg" width="974" height="141"><figcaption>NVAX sentiment and message volume as of November 12 | Source: Stocktwits</figcaption></figure>One user argued that Novavax’s leadership had mishandled the company’s commercial and operational execution, saying the CEO should take responsibility for the company’s small market share despite having what they viewed as a strong&nbsp;COVID-19 vaccine.<stembedurl>https://stocktwits.com/chloeworld5/message/635980396</stembedurl>Another user urged fellow retail investors to contact Shah Capital and state how many shares they own, saying they planned to show support for a potential sale of the company.<stembedurl>https://stocktwits.com/BiggBoy/message/635976305</stembedurl>A third user&nbsp;strongly backed Shah Capital’s campaign and said they were prepared to support the activist as a shareholder, while criticizing the company’s current leadership.<stembedurl>https://stocktwits.com/zulutrix/message/635972537</stembedurl><a href="https://stocktwits.com/symbol/NVAX">Novavax’s stock</a> has declined 10% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Stock Faces Retail Backlash As Shah Capital Warns Of Proxy Fight And Presses For A Sale

Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial results has become “striking.”

Equity

Novavax to Participate in Jefferies London Healthcare Conference

Novavax to Participate in Jefferies London Healthcare Conference Novavax to Participate in Jefferies London Healthcare Conference PR Newswire GAITHERSBURG, Md., Nov. 12, 2025 GAITHERSBURG, Md., Nov...

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know  

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Cantor Fitzgerald Raises Earnings Estimates for Novavax

Novavax, Inc. (NASDAQ:NVAX - Free Report) - Research analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for shares of Novavax in a research report issued on Friday...

Wall Street Zen Downgrades Novavax (NASDAQ:NVAX) to Sell

Wall Street Zen cut Novavax from a "hold" rating to a "sell" rating in a research report on Saturday...

Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised

NVAX exceeds third-quarter expectations, boosted by a Sanofi milestone payment. It lifts its 2025 sales outlook.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

NVAX
Novavax Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NVAX News

NVAXNovavax Inc